Cross-Border Success: Jinxin Fertility’s Revenue Surges 22% Driven by US-China "Dual-Corridor" Strategy

Written By camellia chen

Jinxin Fertility (HK: 1951) released its preliminary FY2025 earnings today, reporting a 22% year-on-year revenue increase. The growth was primarily driven by their "HRC Fertility" US operations, which saw a 40% spike in Chinese patients traveling for PGT-A testing and surrogacy services, now that travel restrictions have fully normalized. Business Insight: This validates the "Domestic + International" hybrid business model. High-net-worth (HNW) Chinese clients are still prioritizing overseas treatment for services restricted at home (like gender selection or surrogacy).

For CMTF agents, this reinforces that the premium market lies in facilitating this cross-border flow, not just domestic cycles.

  1. 【Keywords】: #JinxinFertility #CrossBorderIVF #FinancialResults

  2. 【Source】: Hong Kong Stock Exchange Filings (Jan 29, 2026)

Yang jingdong speaker from Jinxin at CMTF china international conference on assisted reproduction china ivf conference, showing HRC Fertility as well

Yang jingdong from Jinxin International speaks at CMTF Beijing 2025 ( China International Conference On Assisted Reproduction

camellia chen
Previous

Cross-Border Outlook: Thailand and Malaysia See 30% Growth in Chinese Patients for Fertility Preservation
Next

Policy Thaw: Two Chinese Provinces Pilot Oocyte Cryo preservation for Non-Married Women with Medical Indications